Saving changes...

Done

Error

Testing to Target Non-Small Cell Lung Cancer: Managed Care Perspectives

Testing to Target Non-Small Cell Lung Cancer: Managed Care Perspectives

Testing to Target Non-Small Cell Lung Cancer: Managed Care Perspectives

R. Donald Harvey, PharmD, FCCP, BCOP And Matthew Farber, MA
R. Donald Harvey, PharmD, FCCP, BCOP And Matthew Farber, MA
on behalf of Postgraduate Healthcare Education, LLC

FREE
FREE
FREE

FREE
FREE
FREE

null FREE
FREE
FREE
null FREE
FREE
FREE
Normal Price: FREE FREE

Review:

Launch date: 13 Mar 2017
Expiry Date:

Last updated: 15 Mar 2017

Reference: 172104

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

You have null days left.

Description

Recent advancements in the scientific knowledge of non-small cell lung cancer (NSCLC) pathology have shifted the paradigm of care from a "one-size fits all" regimen, to one that focuses on individualized therapy and integrating biomarker-targeted therapies into treatment paradigms. The number of approved and emerging NSCLC targeted therapies tops a dozen. These new cancer agents contribute substantially to improved outcomes for patients as well as rising healthcare costs. Experts indicate that the key to providing cost-effective care is to better match patients with specifically targeted treatment options. This archived webcast will highlight the latest clinical evidence about the role of genetic and molecular targets in developing personalized treatment plans for patients with NSCLC, with a special focus on opportunities for managed care and specialty pharmacists to facilitate individualized care. Expert faculty offer insights on evolving best practices for biomarker testing and interpretation to optimize therapy choice, recent data from the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, and the pharmacoeconomic implications of biomarker-directed NSCLC management.

Objectives

Objectives
At the conclusion of this activity, the participant should be able to:

-ASSESS the role of genetic and molecular biomarkers in guiding NSCLC treatment plans.
-EVALUATE the safety, efficacy, and therapeutic role of new and emerging targeted therapies.
-RECOMMEND pharmacy-driven strategies to facilitate individualized NSCLC management.
R. Donald Harvey, PharmD, FCCP, BCOP And Matthew Farber, MA

Author Information Play Video Bio

R. Donald Harvey, PharmD, FCCP, BCOP And Matthew Farber, MA
on behalf of Postgraduate Healthcare Education, LLC

R. Donald Harvey, PharmD, FCCP, BCOP (Course Director)Associate Professor, Hematology/Medical OncologyDirector, Phase I Clinical Trials SectionWinship Cancer Institute of Emory University Atlanta, Georgia.Matthew Farber, MASenior DirectorOncology Disease StateWalgreens Specialty PharmacyDeerfield, Illinois

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Accreditation Council for Pharmacy Education (ACPE)
  • 1.50 Hours -
    Exam Pass Rate: 75
    -
    Reference: 0064-0000-16-212-H01-P

Faculty and Disclosures

Additional Contributors

null

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error